P-280 Pembrolizumab Versus Physician-Choice Chemotherapy for Previously Treated Patients with Advanced/metastatic Squamous or Adenocarcinoma of the Esophagus or Siewert I Adenocarcinoma of the Esophagogastric Junction (EGJ): Randomized, Phase 3 KEYNOTE-18

Doi Toshihiko,Bennouna Jaafar,Shen Lin,Enzinger Peter,Wang Ruixue,Csiki Ildiko,Koshiji Minori,Shah Manish

DOI: https://doi.org/10.1093/annonc/mdw199.270

IF: 51.769

2016-01-01

Annals of Oncology

Abstract:Background: Programmed death ligand 1 (PD-L1) is frequently overexpressed in esophageal cancer, and its expression has been associated with poor prognosis. Thus, immunotherapy via PD-1/PD-L1 blockade may provide benefit for patients with esophageal cancer. Pembrolizumab is a humanized monoclonal antibody that targets the PD-1 receptor and blocks its interaction with both of its ligands, PD-L1 and PD-L2, thereby permitting activation of an antitumor cytotoxic immune response. In the multicohort, phase 1b KEYNOTE-028 study, pembrolizumab showed manageable toxicity, had an objective response rate (ORR) of 30.4%, and median duration of response was not reached in 23 patients with PD-L1-positive advanced esophageal cancer. The open-label, randomized, multicenter, phase 3 KEYNOTE-181 study (ClinicalTrials.gov, NCT02564263) was designed to compare the efficacy of pembrolizumab to that of single-agent chemotherapy in previously treated patients with advanced/metastatic esophageal cancer. Trial Design: Key eligibility criteria include age ≥18 years; histologically or cytologically confirmed diagnosis of adenocarcinoma or squamous cell carcinoma of the esophagus or Siewert type I adenocarcinoma of the EGJ; metastatic disease or locally advanced, unresectable disease; measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1 (v1.1), as determined by the local site investigator/radiology assessment; documented disease progression during or after first-line therapy; no prior anticancer therapy within 2 weeks of study treatment; Eastern Cooperative Oncology Group performance status 0-1; no active autoimmune disease or brain metastases; and provision of a tissue sample for biomarker analysis. Human epidermal growth factor receptor 2 (HER2) status must be determined for patients with EGJ adenocarcinoma; if HER2 positive, there must be documentation of disease progression on trastuzumab-containing therapy. Eligible patients are to be randomized 1:1 to pembrolizumab 200 mg every 3 weeks or investigator’s choice of one of three standard chemotherapy regimens (paclitaxel 80-100 mg/m2 on days 1, 8, and 15 every 4 weeks, docetaxel 75 mg/m2 every 3 weeks, or irinotecan 180 mg/m2 every 2 weeks). Treatment is to continue until disease progression, unacceptable toxicity, patient withdrawal, investigator decision, or completion of 35 cycles (pembrolizumab only). Adverse events (AEs) are to be monitored throughout treatment and for 30 days thereafter (90 days for serious AEs) and graded per National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Response is to be evaluated every 9 weeks per RECIST v1.1 by central imaging vendor review and per RECIST adapted for immunotherapy response patterns. Patients will be followed every 9 weeks for overall survival (OS) until death, withdrawal of consent, or end of study. Primary efficacy end points are progression-free survival (per RECIST v1.1, blinded central imaging vendor review) and OS. Secondary end points include ORR (per RECIST v1.1, blinded central imaging vendor review). Enrollment in KEYNOTE-181 is ongoing and will continue until approximately 600 patients have enrolled.